

The Medical Letter[®]

on Drugs and Therapeutics

Volume 65

April 3, 2023

ISSUE No.
1673

IN THIS ISSUE

Rezvoglar – Another Insulin Glargine Product Interchangeable with *Lantus*p 56

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 65 (Issue 1673)

April 3, 2023

Take CME Exams

IN BRIEF

Rezvoglar – Another Insulin Glargine Product Interchangeable with Lantus

Insulin glargine-aglr (*Rezvoglar* – Lilly), which was approved by the FDA as a biosimilar to the reference product *Lantus* in 2021 and received interchangeability status with *Lantus* in 2022, will become available in the US on April 1, 2023. It is the second biosimilar insulin product to be designated as interchangeable with *Lantus*; *Semglee* was the first.¹ *Rezvoglar* did not receive interchangeability status with *Lantus* at the time of its initial approval because the manufacturer of *Semglee* had exclusivity for 12 months.

Pronunciation Key

Rezvoglar: rehzh' voh glahr

A biosimilar is a biologic product that is highly similar in composition, strength, and biological properties to the FDA-approved reference product and has no clinically meaningful differences. No new clinical studies were required by the FDA to support approval of interchangeability status. The decision to designate *Rezvoglar* as an interchangeable product was based on a lack of clinically meaningful differences in safety, purity, and potency between *Rezvoglar* and *Lantus*.²

Basaglar is an insulin glargine product that is similar to *Lantus* in composition, strength, and biological properties and has produced comparable clinical results, but it does not have biosimilar or interchangeability status.³

Table 1. Some Insulin Glargine Products¹

Drug	Concentration	Formulations	Cost ²
<i>Lantus</i> (Sanofi)	100 units/mL	10 mL vials	\$292.10
		3 mL <i>SoloStar</i> ³	87.60
<i>Basaglar</i> (Lilly) ⁴	100 units/mL	3 mL <i>KwikPen</i> ³	65.30
<i>Semglee</i> (Biocon) ⁵	100 units/mL	10 mL vials	269.40
		3 mL prefilled pen	80.80
<i>Rezvoglar</i> (Lilly) ⁵	100 units/mL	3 mL <i>KwikPen</i> ³	18.40 ⁶

1. Insulin glargine is also available in 300 unit/mL prefilled pens as *Toujeo*.
2. Approximate WAC for one 10-mL vial or one pen. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly, March 5, 2023. Reprinted with permission by First Databank, Inc. All rights reserved. ©2023. www.fdbhealth.com/drug-pricing-policy.
3. Prefilled disposable pen.
4. Follow-on product similar to *Lantus*. Does not have biosimilar or interchangeability status with *Lantus*.
5. Biosimilar product interchangeable with *Lantus*.
6. Cost according to the manufacturer.

According to federal law, an interchangeable product can be substituted for the reference product by the pharmacist without permission from the prescriber. Some states require the pharmacist to notify the prescriber and/or patient before making the substitution; currently four states (AL, IN, SC, and WA) restrict interchangeability entirely.⁴ ■

1. In brief: *Semglee* – insulin glargine interchangeable with *Lantus*. *Med Lett Drugs Ther* 2021; 63:159.
2. FDA Guidance Document. Clinical immunogenicity considerations for biosimilar and interchangeable insulin products. November 2019. Available at: <https://bit.ly/2VYOJ9I>. Accessed March 16, 2023.
3. Another insulin glargine (*Basaglar*) for diabetes. *Med Lett Drugs Ther* 2017; 59:3.
4. S Jeremias. Part 2: for patients and employers, 2023 means a changed landscape. *AJMC The Center for Biosimilars*. September 13, 2022. Available at: <https://bit.ly/3JL20JP>. Accessed March 16, 2023.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:    

Copyright 2023. ISSN 1523-2859

